# TAISHAN-302 (NCT06612151)

> A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06612151
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Conditions: Small Cell Lung Cancer
- Interventions: YL201; topotecan hydrochloride for injection
- Enrollment: 438
- Primary outcome: To compare the OS of YL201 versus topotecan hydrochloride in subjects with relapsed SCLC.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 38
- Podcasts: 4
- YouTube: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=taishan-302-nct06612151

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06612151", "email": "<work email>"}; the inbox owner confirms by the emailed link.